Disc Medicine Inc. (NASDAQ:IRON) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Leerink Partners raised its price target of the stock to $115 from$110 while reiterating an Outperform rating. Leering Partners Lifts Disc Medicine, Inc. (IRON) Following EPP Drug NDA Application Copyright: mikkolem / 123RF Stock Photo The price target hike comes after the US Food and Drug Administration accepted the company’s New Drug Application for its lead asset, bitopertin, a ...